News from Algeta, Pall and Octapharma – People on the move

By Natalie Morrison

- Last updated on GMT

Related tags Management

in-PharmaTechnologist presents its weekly round-up of the latest career moves within the pharmaceutical industry, including news from Algeta, Pall and Octapharma.

Algeta​ has named Jeffrey Albers​ as president of its new US commercial operation.

Albers will lead the team who will focus on building of sales force, marketing and medical affairs teams for the launch of castration-resistant prostate cancer treatment Alpharadin.

He joins the firm from his position as VP of Genzyme’s haematology and oncology business, now part of Sanofi.

Andrew Kay, Algeta’s President and CEO, said: Working closely with our senior management as part of the executive management team, we are confident his experience and drive will help the establishment of successful commercial operations in the United States, assuming Alpharadin regulatory filing in mid 2012 and subsequent regulatory approval.”

Filtration, separation and purification bod Pall ​has hired Ken Camarco​ as senior VP of global supply chain and business systems.

A veteran of electronics products manufacturer Cooper Industries – where he spent more than 20 years - Camarco will now oversee Pall's plans to integrate its business systems and supply chain with operations.

Larry Kingsley, Pall CEO and president said: “The new Pall Enterprise System will be the means for how we drive customer and process improvement and shareholder return.

“The optimization and simplification of our supply chain is another key priority at Pall.”

David Holliday ​is set to join Octapharma ​as VP of commercial development.

Most recently, Holliday served as VP of global marketing operations and haemophilia with Baxter Bioscience.

He will now be in charge of the firm’s US product marketing, sales and commercial activities, and will oversee development initiatives.

Of Holliday’s appointment, president Flemming Nielsen said: “He joins Octapharma US at an extremely important time for our company as our product portfolio in the US will be increasing significantly in the next year and we expect David will be integral to our growth."

Interphex ​organisers have finalised the 2012 advisory board.

The panel – working on a voluntary basis – is made up of industry experts who will determine the conference’s program.

The members are; Gilead’s senior director of quality operations Dilip Ashtekar​, Richard Poska​ director of regulatory affairs at Abbott, Morrey Atkinson ​who is CSO of R&D at Cook Pharmica, COO of RMC Scott Rudge​, EJ Brandreth​, the VP of quality and regulatory affairs at Althea, VP of business development at Molecular Epidemiology Jaspreet Sidhu, John Gilroy ​senior VP at IPS & Principal
IPS, Russ Somma​ who is president of Somma Tech, VP and CO of Commissioning Agents Timothy Howard​, Robert Timko​, director of AstraZeneca, M.J. Kimmel​ senior director of engineering and facilities for Cephalon, Chad Wachter​ senior CMC manager at BTG, Albert Manigo-Bey​ manager of
procurement at Watson Pharmaceuticals, Michael Zupon​ VP of pharmaceutical and manufacturing technology at MannKind Corporation, and Sanjay Patel​ who is senior director of global materials management for Shire.

in-PharmaTechnologist will attend Interphex this April. If you would like to get in touch with us regarding our place at the conference, please send us an email and we hope to see you there!

Related topics Bio Developments

Related news

Follow us